← All trials
NCT07309562
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2025
- Primary completion
- Mar 31, 2028
- Completion date
- May 7, 2028
- First posted
- Dec 30, 2025
- Last posted
- Dec 30, 2025
- Enrollment
- 141
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen Amoytop Biotech Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.